RA Capital Management’s Phathom Pharmaceuticals PHAT Stock Holding History

RA Capital Management’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,115,008	Closed	-$61.3M	–	103
2021 Q4	$61.3M	Hold	3,115,008	–	–	1.08%	27
2021 Q3	$100M	Hold	3,115,008	–	–	1.39%	23
2021 Q2	$105M	Hold	3,115,008	–	–	1.69%	16
2021 Q1	$117M	Sell	3,115,008 -710,000	-19%	-$29.7M	1.76%	14
2020 Q4	$127M	Hold	3,825,008	–	–	1.78%	13
2020 Q3	$140M	Hold	3,825,008	–	–	2.57%	8
2020 Q2	$126M	Buy	3,825,008 +117,600	+3%	+$4.52M	2.45%	12
2020 Q1	$95.7M	Buy	3,707,408 +60,600	+2%	+$2.03M	3.02%	11
2019 Q4	$114M	Buy	+3,646,808	New	+$91.7M	3.44%	9

Other funds holding PHAT

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Invesco Atlanta, Georgia $653B AUM 32.41% 1-Year Est. Return

Janus Henderson Group

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Ensign Peak Advisors

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM